| Outcome Measures: |
Primary: Maximum Observed Concentrations (Cmax) of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets, Days 1, 2, and 3 of Periods 1 and 2|AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets, AUC=Area under the concentration-time curve, Days 1, 2, and 3 of Periods 1 and 2|AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf]) for Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets, AUC=Area Under the Concentration-time Curve, Days 1, 2, and 3 of Periods 1 and 2 | Secondary: Number of Participants With Death as Outcome and Serious Adverse Events (SAEs), SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization., Continuously, from screening through Day 1 to within 30 days of drug discontinuation on Day 1
|
